Terms: = Skin cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR
286 results:
1. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
[TBL] [Abstract] [Full Text] [Related]
2. Adoptive T cell therapy for solid tumors: current landscape and future challenges.
Albarrán V; San Román M; Pozas J; Chamorro J; Rosero DI; Guerrero P; Calvo JC; González C; García de Quevedo C; Pérez de Aguado P; Moreno J; Cortés A; Soria A
Front Immunol; 2024; 15():1352805. PubMed ID: 38550594
[TBL] [Abstract] [Full Text] [Related]
3. Adoptive cell therapy for solid tumors beyond car-T: Current challenges and emerging therapeutic advances.
Zhang T; Tai Z; Miao F; Zhang X; Li J; Zhu Q; Wei H; Chen Z
J Control Release; 2024 Apr; 368():372-396. PubMed ID: 38408567
[TBL] [Abstract] [Full Text] [Related]
4. Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm cancer Therapy Owing to Precision Targeting of CD123.
Zanotta S; Galati D; De Filippi R; Pinto A
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338733
[TBL] [Abstract] [Full Text] [Related]
5. car-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes.
Jilani S; Saco JD; Mugarza E; Pujol-Morcillo A; Chokry J; Ng C; Abril-Rodriguez G; Berger-Manerio D; Pant A; Hu J; Gupta R; Vega-Crespo A; Baselga-Carretero I; Chen JM; Shin DS; Scumpia P; Radu RA; Chen Y; Ribas A; Puig-Saus C
Nat Commun; 2024 Feb; 15(1):1244. PubMed ID: 38336975
[TBL] [Abstract] [Full Text] [Related]
6. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Rodriguez-Otero P; van de Donk NWCJ; Pillarisetti K; Cornax I; Vishwamitra D; Gray K; Hilder B; Tolbert J; Renaud T; Masterson T; Heuck C; Kane C; Verona R; Moreau P; Bahlis N; Chari A
Blood Cancer J; 2024 Feb; 14(1):24. PubMed ID: 38307865
[TBL] [Abstract] [Full Text] [Related]
7. carney complex predisposes to breast cancer: prospective study of 50 women.
Vaduva P; Violon F; Jouinot A; Bouys L; Espiard S; Bonnet-Serrano F; North MO; Cardot-Bauters C; Raverot G; Hieronimus S; Lefebvre H; Nunes ML; Tabarin A; Groussin L; Assié G; Sibony M; Vantyghem MC; Pasmant E; Bertherat J
Eur J Endocrinol; 2024 Feb; 190(2):121-129. PubMed ID: 38252880
[TBL] [Abstract] [Full Text] [Related]
8. Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma.
Goyal A; Foss F
Expert Rev Anticancer Ther; 2024; 24(1-2):41-58. PubMed ID: 38224371
[TBL] [Abstract] [Full Text] [Related]
9. Nanocatalytic Anti-Tumor Immune Regulation.
Li M; Jiang H; Hu P; Shi J
Angew Chem Int Ed Engl; 2024 Mar; 63(13):e202316606. PubMed ID: 38212843
[TBL] [Abstract] [Full Text] [Related]
10. Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies.
Raghani NR; Chorawala MR; Mahadik M; Patel RB; Prajapati BG; Parekh PS
Med Oncol; 2024 Jan; 41(2):51. PubMed ID: 38195781
[TBL] [Abstract] [Full Text] [Related]
11. Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies.
Zhang Z; Markmann C; Yu M; Agarwal D; Rostami S; Wang W; Liu C; Zhao H; Ochoa T; Parvathaneni K; Xu X; Li E; Gonzalez V; Khadka R; Hoffmann J; Knox JJ; Scholler J; Marcellus B; Allman D; Fraietta JA; Samelson-Jones B; Milone MC; Monos D; Garfall AL; Naji A; Bhoj VG
Cell Rep Med; 2023 Dec; 4(12):101336. PubMed ID: 38118406
[TBL] [Abstract] [Full Text] [Related]
12. Harnessing immunotherapy for brain metastases: insights into tumor-brain microenvironment interactions and emerging treatment modalities.
Zhou D; Gong Z; Wu D; Ma C; Hou L; Niu X; Xu T
J Hematol Oncol; 2023 Dec; 16(1):121. PubMed ID: 38104104
[TBL] [Abstract] [Full Text] [Related]
13. car NK Cell Therapy for the Treatment of Metastatic Melanoma: Potential & Prospects.
Hibler W; Merlino G; Yu Y
Cells; 2023 Nov; 12(23):. PubMed ID: 38067178
[TBL] [Abstract] [Full Text] [Related]
14. Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors.
Yoshimoto S; Chester N; Xiong A; Radaelli E; Wang H; Brillantes M; Gulendran G; Glassman P; Siegel DL; Mason NJ
MAbs; 2023; 15(1):2287250. PubMed ID: 38047502
[TBL] [Abstract] [Full Text] [Related]
15. CSPG4 car-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma.
Giraudo L; Cattaneo G; Gammaitoni L; Iaia I; Donini C; Massa A; Centomo ML; Basiricò M; Vigna E; Pisacane A; Picciotto F; Berrino E; Marchiò C; Merlini A; Paruzzo L; Poletto S; Caravelli D; Biolato AM; Bortolot V; Landoni E; Ventin M; Ferrone CR; Aglietta M; Dotti G; Leuci V; Carnevale-Schianca F; Sangiolo D
J Exp Clin Cancer Res; 2023 Nov; 42(1):310. PubMed ID: 37993874
[TBL] [Abstract] [Full Text] [Related]
16. Pigmented epithelioid melanocytoma arising from a teratoma of a carney complex patient.
Ichiki T; Ito T; Oishi H; Kato K; Oda Y; Nakahara T
J Obstet Gynaecol Res; 2024 Feb; 50(2):266-269. PubMed ID: 37985470
[TBL] [Abstract] [Full Text] [Related]
17. Combining CSPG4-car and CD20-CCR for treatment of metastatic melanoma.
Teppert K; Winter N; Herbel V; Brandes C; Lennartz S; Engert F; Kaiser A; Schaser T; Lock D
Front Immunol; 2023; 14():1178060. PubMed ID: 37901209
[TBL] [Abstract] [Full Text] [Related]
18. Targeting the melanoma-associated antigen CSPG4 with HLA-C*07:01-restricted T-cell receptors.
Kropp KN; Fatho M; Huduti E; Faust M; Lübcke S; Lennerz V; Paschen A; Theobald M; Wölfel T; Wölfel C
Front Immunol; 2023; 14():1245559. PubMed ID: 37849763
[TBL] [Abstract] [Full Text] [Related]
19. Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor T Cells: The Intersection of Stem Cells and Immunotherapy.
Lahimchi MR; Maroufi F; Maali A
Cell Reprogram; 2023 Oct; 25(5):195-211. PubMed ID: 37782910
[TBL] [Abstract] [Full Text] [Related]
20. Brave new world-new and emerging treatments for gastric cancer.
Lynch E; Duffy AG; Kelly RJ
Chin Clin Oncol; 2023 Oct; 12(5):54. PubMed ID: 37691344
[TBL] [Abstract] [Full Text] [Related]
[Next]